These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 26887217)

  • 1. [Acupuncture Intervention Reduced Weight Gain Induced by Hypoglycemic Agents through Food Intake-related Targets in Central Nervous System].
    Jing XY; Ou C; Lu SF; Zhu BM
    Zhen Ci Yan Jiu; 2015 Dec; 40(6):510-3. PubMed ID: 26887217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain.
    Aubert G; Burnier M; Dulloo A; Perregaux C; Mazzolai L; Pralong F; Zanchi A
    Metabolism; 2010 Jan; 59(1):25-32. PubMed ID: 19793594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A role for central nervous system PPAR-γ in the regulation of energy balance.
    Ryan KK; Li B; Grayson BE; Matter EK; Woods SC; Seeley RJ
    Nat Med; 2011 May; 17(5):623-6. PubMed ID: 21532595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress of Research on Mechanism of Acupuncture for Diabetes Mellitus].
    Chen C; Wang HC; Zhai X; Huang F; Wu D; Rong PJ
    Zhen Ci Yan Jiu; 2018 Sep; 43(9):601-5. PubMed ID: 30232872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiazolidinediones, insulin resistance and obesity: Finding a balance.
    Wilding J
    Int J Clin Pract; 2006 Oct; 60(10):1272-80. PubMed ID: 16981971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
    Mack CM; Moore CX; Jodka CM; Bhavsar S; Wilson JK; Hoyt JA; Roan JL; Vu C; Laugero KD; Parkes DG; Young AA
    Int J Obes (Lond); 2006 Sep; 30(9):1332-40. PubMed ID: 16534527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinedione safety.
    Kung J; Henry RR
    Expert Opin Drug Saf; 2012 Jul; 11(4):565-79. PubMed ID: 22616948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
    Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R; ;
    Circulation; 2003 Dec; 108(23):2941-8. PubMed ID: 14662691
    [No Abstract]   [Full Text] [Related]  

  • 11. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of thiazolidinediones.
    Tolman KG
    Expert Opin Drug Saf; 2011 May; 10(3):419-28. PubMed ID: 21366501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J; Scheen AJ
    Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System.
    Ramos-Nino ME; MacLean CD; Littenberg B
    BMC Med; 2007 Jun; 5():17. PubMed ID: 17584937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential role of thiazolidinediones in atrial fibrillation.
    Liu T; Korantzopoulos P; Li G; Li J
    Int J Cardiol; 2008 Aug; 128(1):129-30. PubMed ID: 17655946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marrow suppression with myelodysplastic features, hypoerythropoetinemia, and lipotrophic proptosis due to rosiglitazone.
    Clevidence DE; Juckett MB; Lucarelli MJ
    WMJ; 2009 Dec; 108(9):462-5. PubMed ID: 20131689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the future of thiazolidinediones (TZDs) after market introduction of inhaled insulin?
    Curtiss FR
    J Manag Care Pharm; 2006 Mar; 12(2):169-72. PubMed ID: 16515377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine competes for the peroxisome proliferator-activated receptor nuclear receptors.
    Hayden MR
    J Cardiometab Syndr; 2008; 3(1):70-1. PubMed ID: 18326982
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.